Spherix Global Insights

September 30, 2021

AbbVie Pressures Biohaven in Migraine Prevention with FDA Approval for its CGRP Blockbuster-to-be Qulipta

From: FiercePharma

By: Angus Liu



Tuesday, AbbVie said the FDA has green-lighted its Qulipta, or atogepant, for prevention of episodic migraine. The go-ahead follows the landmark approval of Biohaven’s Nurtec ODT as the first oral anti-CGRP drug for preventing migraine, setting up a direct battle between two meds that both bear big sales expectations.

Doctors’ initial feedback for Nurtec suggests a strong launch for the Biohaven med in the prevention setting. A recent survey of 100 neurologists Raymond’s team conducted with Spherix Global Insights indicated that Nurtec has captured 6% of the episodic migraine prevention market merely four months into its FDA go-ahead. That’s compared to 11% for Aimovig and 9% for Emgality…(read more)